Understanding the immune system and metabolism in patients with acute leukemia
Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia
This study looks at how the immune system and metabolism change in people with acute leukemia before and after treatment to see how these changes affect their response to therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 170 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bologna, Bologna) |
| Trial ID | NCT06814444 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the immunophenotypic and immunometabolic profiles of patients diagnosed with acute leukemia, both before and after therapy. It will assess the relationship between the molecular and metabolic characteristics of leukemia cells and the surrounding immune system, identifying immune-modulatory mechanisms activated by malignant cells. Additionally, the study will explore how immunometabolic signatures correlate with therapy responses and investigate the role of extracellular vesicles in regulating immune cell metabolism. Samples will be collected from patients and healthy controls during routine care visits.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with acute leukemia and are eligible for treatment involving chemotherapy or innovative therapies.
Not a fit: Patients who do not have a diagnosis of acute leukemia or are not eligible for any treatment schemes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of how the immune system interacts with leukemia, potentially leading to improved treatment strategies.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding the immune response in cancer, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: PATIENT * Diagnosis of Acute Leukaemia. * Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies. * age ≥ 18 years. * Signature of informed consent by patients at the time of diagnosis. Healthy donors (AIL BOLOGNA ODV volunteers) * age ≥ 18 years. * Signature of informed consent. Exclusion Criteria: * no one
Where this trial is running
Bologna, Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Antonio Curti, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Antonio Curti, MD
- Email: antonio.curti2@unibo.it
- Phone: +39 0512144074
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.